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Impact of calibration on estimates of central blood pressures
This article has been corrected since Advance Online Publication and a corrigendum is also published in this issue.
TK Soender,1, LM Van Bortel2, JE Møller3, J Lambrechtsen4, J Hangaard5 and K Egstrup1
Using the Sphygmocor device it is recommended that the radial pressure wave is calibrated for brachial systolic blood pressure
(SBP) and diastolic blood pressure (DBP). However it has been suggested that brachial-to-radial pressure ampliﬁcation causes
underestimation of central blood pressures (BPs) using this calibration. In the present study we examined if different
calibrations had an impact on estimates of central BPs and on the clinical interpretation of our results. On the basis of
ambulatory BP measurements, patients were categorized into patients with controlled, uncontrolled or resistant hypertension.
We ﬁrst calibrated the radial pressure wave as recommended and afterwards recalibrated the same pressure wave using
brachial DBP and calculated mean arterial pressure. Recalibration of the pressure wave generated signiﬁcantly higher estimates
of central SBP (P¼ 0.0003 and Po0.0001 at baseline and P¼ 0.0001 and P¼ 0.0002 after 6 months). Using recommended
calibration we found a signiﬁcant change in central SBP in both treatment groups (P¼ 0.05 and P¼ 0.01), however, after
recalibrating signiﬁcance was lost in patients with resistant hypertension (P¼ 0.15). We conclude that calibration with DBP and
mean arterial pressure produces higher estimates of central BPs than recommended calibration. The present study also shows
that this difference between the two calibration methods can produce more than a systematic error and has an impact on
interpretation of clinical results.
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INTRODUCTION
Since publication of the Conduit Artery Function Evaluation
study,1 interest in noninvasive estimation of central blood
pressure (BP) has increased both in research and in clinical
practice. BP is usually measured at the level of the brachial artery;
however, because of pulse pressure (PP) ampliﬁcation, BP
measured at the level of the brachial artery does not always
match the BP measured at the aortic level.2 It has been shown that
the aortic pressure and thus the load on the left ventricle can be
elevated despite brachial BP being within normal range.3 As such,
central BP has been shown to produce additive information when
evaluating cardiovascular risk.4
Several devices for noninvasive estimation of central BP exist.5 The
Sphygmocor makes use of applanation tonometry. The peripheral
pressure wave is measured over the radial artery. The built in
generalized transfer function in the Sphygmocor then generates an
estimate of the pressure wave at the aorta. Central BP can be
estimated from this generated central pressure wave.6 The general-
ized transfer function has been validated in several studies.7 - 9
It has been recommended by the manufacturer that calibration
of the radial pressure wave is done using brachial systolic BP (SBP)
and diastolic BP (DBP).10 It has previously been shown that
brachial-to-radial PP ampliﬁcation can produce quite large
differences between brachial and radial BP. To overcome the
problem of possible brachial-to-radial pressure ampliﬁcation, it has
been suggested to calibrate the radial pressure wave for DBP and
mean arterial BP instead, as these pressures are fairly stable
throughout the large artery tree.11
The present study investigates whether the calibration method
of the radial pressure wave changes estimates of central BPs and if
it has an impact on the clinical interpretation of response to
therapy in a population of patients with type II diabetes mellitus
receiving intensiﬁed antihypertensive treatment.
METHODS
Study population
Patients from the diabetes out-patient clinic at the University Hospital of
Odense, Svendborg Hospital, Denmark, were screened for eligibility.
Inclusion criteria were type II diabetes, hypertension and being between
18 and 80 years old. Exclusion criteria were atrial ﬂutter or ﬁbrillation, a
plasma creatinine above 200mmol l1 and known non-adherence to therapy.
All examinations were performed by the same trained technician.
The study was approved by the ethics committee of the Region of
Southern Denmark and conducted in agreement with the Helsinki
declaration of 2009.12 All patients provided written informed consent.
BP measurement
Clinic BP measurements were performed using Omron model HEM-757
(Omron Healthcare, Brøndby, Denmark). The device was calibrated at the
beginning of the study and thereafter once a year according to
manufacturer’s instructions. Patients were at rest for at least 5min, sitting
comfortably in a chair with no legs crossed and their back supported. The
patients’ arms were supported at heart level and cuff size was chosen
according to the guidelines. BP was measured once in each arm. If the
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difference between the patient’s arms was more than 10%, BP was
measured in the arm with the highest BP. Throughout the study BP was
measured at the same arm. BP was measured at least three times and the
mean value of all the three measurements was used. If measurements
differed more than 5%, additional readings were performed and the
readings with the least variability were used.13
Ambulatory BP measurement (ABPM) was performed using Kivex TM
2430 (Kivex, Hoersholm, Denmark) and Spacelab 90217 (Spacelabs
Healthcare, Washington, DC, USA) devices. Devices were calibrated at
the beginning of the study and thereafter once a year according to the
manufacturer’s instructions. Patients always had their ABPM measured
using the same device. Cuff size was chosen according to the instructions.
The ﬁrst reading of the ABPM was compared with the clinic BP. Both
devices were preprogrammed to measure with intervals of 15min from
0700 to 2300 hours and 30min from 2300 to 0700 hours. An ABPM was
considered successful when there were at least 14 daytime readings and 7
nighttime readings according to the guidelines from the European Society
of Hypertension, and when number of successful readings was X70%.
When the ABPM device was demounted, patients were asked about their
sleeping habits and whether they had been disturbed by the device during
the nighttime.14
Patients were characterized as controlled, uncontrolled and resistant
hypertensives based on the ABPM and number of antihypertensive agents
according to the recommendations from the American Heart Association.15
Resistant hypertension (RH) was deﬁned as uncontrolled BP (4130/
80mmHg) on three or more antihypertensive agents, or controlled BP on
four or more antihypertensive agents, of which one should ideally be a
diuretic.15 Compliance was examined by endorsed prescriptions. It was
assumed that if the patient had bought the prescribed antihypertensive
agent, then he or she also took the medicine. Patients that were found to
be noncompliant were excluded from the data analysis.
Both clinic BP and ABPM were performed at baseline and at the end of
the follow up period. During this follow up period patients with controlled
hypertension (CH) did not have any changes in their antihypertensive
treatment performed by us and served as the control group. Patients with
uncontrolled (UH) and RH had their antihypertensive treatment changed
according to the guidelines from the European Society of Hypertension.
Pulse wave analysis
Pulse wave analysis was performed using Sphygmocor (AtCor Medical,
West Ryde, NSW, Australia). Patients were at rest in supine position for
15min in a quiet room. Patients were not allowed to talk during the
examination and had restrained from eating, smoking, drinking coffee and
alcohol for at least 8h prior to examination according to recommendations.16
Furthermore, they did not take their morning medication on the day of
examination.
The aortic pressure wave was estimated by the generalized transfer
function using Sphygmocor. Sphygmocor was ﬁrst calibrated using
brachial SBP and DBP, and then recalibrated using brachial DBP and
mean arterial pressure (MAP). MAP was estimated using the PP method:
MAP¼DBPþ 0.4 PP.17 Radial tonometry was performed twice. The
pressure wave was accepted when operator index was above 80 and
the pressure wave with the highest operator index was chosen for further
analysis.10 Analysis of the pressure wave was done ofﬂine in customized
software using Matlab.18 - 20
Pulse wave analysis was performed at baseline and after 6 months.
Statistical analysis
Statistical analysis was performed using Stata11 (Statacorp LP, College
Station, TX, USA) and SPSS 19. Data were expressed as medians and
interquartile ranges because of asymmetrical distribution. We used linear
regression to examine differences between groups and Student’s paired
t-test for estimation of changes in BPs. Data were transformed with log or
inverse transformation after using the ladder function in Stata, and residual
plots were employed to test for normal distribution of data after
transformation. Bland--Altman plots were used to analyze systematical
differences between the two different calibrations. A P-value of 0.05 was
considered statistically signiﬁcant.
RESULTS
Median follow-up time in the present study was 6 months with full
and interquartile ranges of 2 to 18 months and 5 to 8 months,
respectively. In 29 out of 122 (E22%) patients included in the
study, the operator index of pulse wave analysis was below 80.
These patients were subsequently excluded from analysis leaving
93 patients.
Patients with CH, UH and RH were comparable to the exception
of BPs and antihypertensive treatment (Table 1). Patients with UH
and RH had signiﬁcantly higher ambulatory BP than patients with
CH. Estimated glomerular ﬁltration rate was nonsigniﬁcantly
decreased in patients with RH as compared with those with CH
and UH (P¼ 0.07).
As expected, peripheral and central SBP differed signiﬁcantly in
all hypertension groups, both at baseline and after 6 months,
when brachial SBP and DBP were used for calibration (Figures 1
and 2). When calibrating for DBP and MAP, the difference between
peripheral and central BP at baseline remained signiﬁcant,
however, after 6 months these differences were not signiﬁcant
anymore in patients with RH.
Overall, the central SBP was 6.1±14.6-mmHg higher at baseline
and 6.6±22.0-mmHg higher after 6 months when calibrated for
DBP and MAP instead of brachial SBP and DBP. Correlation between
the differently calibrated estimates of central SBP was good with
r2¼ 0.84 at baseline and r2¼ 0.78 after 6 months. When divided into
hypertension groups, the difference in central SBP ranged from 4.5
to 9.6mmHg. As shown in Figure 1, these values of central SBP were
all signiﬁcantly higher both at baseline and after 6 months.
Table 1. Patient characteristics at baseline
Variable Controlled hypertension (N¼ 32) Uncontrolled hypertension (N¼ 30) Resistant hypertension (N¼ 31)
Sex (male %) 59 69 78
Age (years) 66 (58;68) 59 (55;67) 64 (58;67)
Duration of diabetes (years) 11 (6;16) 11 (7;15) 11 (8;14)
Body mass index 32 (27;37) 31 (28;34) 32 (30;38)
Ambulatory systolic blood pressure (mmHg) 123 (118;127) 140 (135;150)* 139(132;146)*
Ambulatory pulse pressure (mmHg) 53 (47;57) 62 (55;69)* 65 (61;70)*
Number of antihypertensive agents 2 (1;3) 2 (1;2) 4 (3;4)*
Total cholesterol (mmol l1) 4.1 (3.8;4.8) 4.2 (3.5;4.9) 3.9 (3.4;4.6)
Low density lipoprotein (mmol l1) 2.2 (1.9;2.7) 2.1 (1.7;2.5) 2 (1.6;2.4)
Estimated glomerular filtration rate (mlmin1) 96 (70;115) 99 (70;120) 82 (52;103)
Data are numbers, percentages or median (range); *Po0.0001 versus controlled hypertension. Differences between hypertension groups were examined
using univariate linear regression on transformed data for continuous variables and w2 test for categorical data.
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After 6-months intensiﬁed antihypertensive treatment, we
found no signiﬁcant changes in peripheral or central SBP in
patients with CH using either of the calibrations (Figure 2). In the
two treatment groups, however, the reduction in peripheral SBP
was statistically signiﬁcant as was the reduction in central
SBP, when the pressure wave was calibrated using brachial SBP
and DBP. When calibrating the pressure wave for DBP and
MAP we only found the reduction in patients with UH to be
signiﬁcant.
The two calibration methods led to different changes in central
BP. In 42 patients, an inverse change in SBP was observed when
calibration was changed. Figures 3 and 4 show Bland--Altman
plots comparing central SBPs obtained with the two methods at
baseline and after 6 months, respectively.
DISCUSSION
The present study conﬁrms that the calibration method of the
radial pressure wave leads to different results of aortic BP using
the Sphygmocor device. Calibration with brachial SBP and DBP
resulted in lower central systolic pressure than calibration with
mean and DBP. More importantly, it also shows that the difference
is not systematic and that this may lead to divergent conclusions
in clinical studies.
Figure 1. Differences between peripheral and central SBP with different calibration methods. Values are reported as medians and interquartile
ranges. Statistical significance between peripheral and central BP, and central BP with different calibration methods were tested using
Student’s t-test on inverse-transformed data.
Figure 2. Differences in changes of peripheral and central SBP with different calibration over 6 months with intensified antihypertensive
treatment. Values are reported as medians and interquartile ranges. Statistical significance of changes in BP between peripheral and central
BP, and central BP with different calibration methods were tested using linear regression on non-transformed data.
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Verbeke et al.11 suggested that a signiﬁcant part of the
difference in estimates of central BP between the Sphygmocor
device and other methods was due to omission of the brachial-to-
radial pressure ampliﬁcation and not so much due to the use of
the generalized transfer function. The problem of brachial-to-
radial pressure ampliﬁcation could theoretically be overcome by
using the more steady components of BP, which are DBP and
MAP, instead of the recommended calibration with brachial SBP
and DBP, as the steady components of pressure do not vary
noticeably throughout the large artery tree. The approach in our
study however is different from that of Verbeke et al. In the
present study, brachial BP was measured prior to performing
applanation tonometry, and the brachial SBP and DBP were
entered in the Sphygmocor software as recommended to calibrate
the radial pressure wave. Thereafter, the same generated radial
pressure wave was calibrated with DBP and MAP obtained from
the 40% PP formula using the Sphygmocor software, whereas
Verbeke calculated MAP from a brachial pressure wave obtained
with applanation tonometry. As such, the only difference between
the two calibration methods in the present study was the use of
MAP instead of brachial SBP.
In the present study, recalibrating the radial pressure wave with
DBP and MAP produced estimates of central BPs being on average
6-mmHg higher than when using the recommended brachial
systolic --diastolic calibration. Despite good correlation (r2E0.8), a
large variation between the two calibration methods was found,
being for central SBP ±20mmHg. This variation of difference
between calibrations is not only statistically signiﬁcant but also
highly relevant in a clinical setting.
The difference between the two calibration methods can at
least in part be explained by the omission of the brachial-to-radial
pressure ampliﬁcation with the recommended brachial systolic --
diastolic calibration. In addition, the generalized 40% PP method
to estimate MAP from brachial BP is also likely to contribute to the
difference between the two calibration methods.
It has been assumed that the underestimation of central BPs
with the recommended Sphygmocor procedure is a systematic
underestimation and that the results and conclusions therefore
would not differ because of it.1 This is not the case in the present
study.
Recalibration of the pressure pulse wave with DBP and MAP
caused the central SBP to increase or decrease inversely of what
was seen with recommended calibration in 42 patients (E45%)
after 6 months. This could be due to the fact that pressure
ampliﬁcation is not constant in different parts of the vascular tree
and can differ regionally according to factors, such as local
vasodilatory status.
In addition, and even more important, in the present study the
interpretation of the results changed according to the calibration
methods. Using the recommended brachial systolic --diastolic
calibration, we could conclude that the reduction in central SBP
after 6-months intensiﬁed antihypertensive treatment was statis-
tically signiﬁcant in both treatment groups, whereas when using
DBP and MAP for calibration of the pressure wave the reduction in
central SBP in patients with RH was nonsigniﬁcant. Some studies,
including the Strong Heart Study,4 have already used DBP and
MAP for calibration of the pressure wave and the present study
suggests that the choice of calibration may be important in
determining an individual patient’s risk proﬁle and in evaluating
the effect of antihypertensive therapy on central BP.
In conclusion, the use of different calibration methods produces
more than a systematic error and can lead to different
Figure 3. Bland--Altman plot of differences and means of central
SBP using two different calibrations at baseline.
Figure 4. Bland--Altman plot of differences and means of central
SBP using two different calibrations after 6 months.
What is known about this topic
 Pulse pressure amplification in the upper limb: It is well known
that there is an amplification of the pulse pressure in the upper
limb and that this might introduce an error when calibrating
the radial pressure wave with brachial blood pressure for
estimation of central blood pressure.
 Calibration: It is recommended to calibrate the radial pressure
wave with brachial blood pressure, but it has been
demonstrated that this generates lower estimates of central
blood pressures when compared with those obtained
invasively.
 Clinical relevance: It has been assumed that calibration of the
radial pressure wave with brachial blood pressures merely
introduces a systematic error.
What this study adds
 More than a systematic error: We demonstrate that calibration
with systolic and diastolic blood pressure generates more than
a systematic error.
 Significantly higher estimates of central blood pressure: We
demonstrate that recalibration with mean arterial pressure and
diastolic blood pressure generates significantly higher
estimates of central blood pressures.
 Highly clinically relevant: Recalibration of the radial pressure
wave with mean arterial pressure and diastolic blood pressure
has a highly relevant clinical impact as we show that it changes
interpretation of the results in the present study.
Impact of calibration
TK Soender et al
709
Journal of Human Hypertension (2012) 706 - 710& 2012 Macmillan Publishers Limited
conclusions, which could be of clinical importance for the
individual patient if central BP is to be used to predict individual
cardiovascular risk or treatment response.
Limitations
There are several limitations to this study. First of all it is
conducted in high-risk patients and as such we cannot be certain
that the same results would be obtained in a healthy population.
Furthermore, we have not been able to compare our results with
invasive measures.
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